Similar articles

Abstract: Objective: The aim of this study was to formulate polymer-based artesunate nanoparticles for malaria treatment. Methods: Artesunate was loaded with poly(D,l-lactic-co-glycolic acid) (PLGA) by solvent evaporation from an oil-in-water single emulsion. Nanoparticles were characterized by X-ray diffraction and differential scanning calorimetry analyses. In vivo antimalarial studies at 4 mg/kg were performed on Swiss male albino mice infected with Plasmodium berghei. Hematological and hepatic toxicity assays were performed. In vitro cytotoxicity of free and encapsulated artesunate (Art-PLGA) to cell line RAW 264.7 was determined at concentrations of 7.8–1000 µg/ml. Results: The particle size of the formulated drug was (329.3±21.7) nm and the entrapment efficiency was (38.4±10.1)%. Art-PLGA nanoparticles showed higher parasite suppression (62.6%) compared to free artesunate (58.2%, P<0.05). Platelet counts were significantly higher in controls (305 000.00±148 492.40) than in mice treated with free artesunate (139 500.00±20 506.10) or Art-PLGA (163 500.00±3535.53) (P<0.05). There was no sign of hepatic toxicity following use of the tested drugs. The half maximal inhibitory concentration (IC₅₀) of Art-PLGA (468.0 µg/ml) was significantly higher (P<0.05) than that of free artesunate (7.3 µg/ml) in the in vitro cytotoxicity assay. Conclusions: A simple treatment of PLGA-entrapped artesunate nanoparticles with dual advantages of low toxicity and better antiplasmodial efficacy has been developed.

基于聚乳酸羟乙酸共聚物的青蒿琥酯纳米颗粒的制备，及其抗疟活性和毒性评价

[1]Acharya, S., Sahoo, S.K., 2011. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Del. Rev., 63(3):170-183.

[2]Agnihotri, J., Singh, S., Bigonia, P., 2013. Formal chemical stability analysis and solubility analysis of artesunate and hydroxychloroquinine for development of parenteral dosage form. J. Pharm. Res., 6:117-122.

[3]Anitha, A., Deepagan, V.G., Rani, V.V.D., et al., 2011. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohyd. Poly., 84(3):1158-1164.

[4]Bhawana, R.K., Basniwal, H.S., Buttal, V.K., et al., 2011. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. J. Agric. Food Chem., 59(5):2056-2061.

[5]Bigoniya, P., Sahu, T., Tiwari, V., 2015. Hematological and biochemical effects of sub-chronic artesunate exposure in rats. Toxicol. Rep., 2:280-288.

[6]Chadha, R., Gupta, S., Pathak, N., 2012. Artesunate-loaded chitosan/lecithin nanoparticles: preparation, characterization, and in vivo studies. Drug Dev. Ind. Pharm., 38(12):1538-1546.

[7]Cheesbrough, M., 1998. District Laboratory Practice in Tropical Countries. Part 1. Cambridge University Press, London.

[8]Chinaeke, E.E., Chime, S.A., Onyishi, V.I., et al., 2015. Formulation development and evaluation of the anti-malaria properties of sustained release artesunate-loaded solid lipid microparticles based on phytolipids. Drug Deliv., 22(5):652-665.

[9]Chittasupho, C., Xie, S.X., Baoum, A., et al., 2009. ICAM-1 targeting of doxorubicinloaded PLGA nanoparticles to lung epithelial cells. Eur. J. Pharm. Sci., 37(2):141-150.

[10]Clark, R.L., 2012. Effects of artemisinins on reticulocyte counts and and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Def. Res. Part A: Clin. Mol. Teratol., 94(2):61-75.

[11]Cooper, D.L., Harirforoosh, S., 2014. Design and optimization of PLGA-based diclofenac loaded nanoparticles. PLoS ONE, 9(1):e87326.

[12]des Rieux, A., Fievez, V., Garinot, M., et al., 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control Release, 116(1):1-27.

[13]Dikasso, D., Makonnen, E., Debella, A., et al., 2006. In vivo anti-malaria activity of hydroalcoholic extract from Asparaginus africanus in mice infected with Plasmodium berghei. Ethiop. J. Health Dev., 20(2):112-118.

[14]Efferth, T., 2007. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med., 73(4):299-309.

[15]Faber, J.L., Chein, K.R., Mitlnacht, S., 1981. Myocardial ischemia: the pathogenesis of irreversible cell injury in ischemia. Am. J. Pathol., 102(2):271-281.

[16]Ibrahim, N., Ibrahim, H., Dormoi, J., et al., 2014. Albumin-bound nanoparticles of practically water-soluble antimalarial lead greatly enhance its efficacy. Int. J. Pharm., 464(1-2):214-224.

[17]Jain, R.A., 2000. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 21(23):2475-2490.

[18]Kumari, A., Yadav, S.K., Yadav, S.C., 2010. Biodegradable polymeric nanoparticles based drug delivery systems. Coll. Surf. B: Biointer., 75(1):1-18.

[19]Lai, S.K., O'Hanlon, D.E., Harrold, S., et al., 2007. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl. Acad. Sci. USA, 104(5):1482-1487.

[20]Liu, W.M., Gravett, A.M., Dalgleish, A.G., 2011. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int. J. Cancer, 128(6):1471-1480.

[21]Mainardes, R.M., Evangelista, R.C., 2005. PLGA nanoparticles containing praziquantel effect of formulation variables on size distribution. Int. J. Pharm., 290(1-2):137-144.

[22]McNeil, S.E., 2005. Nanotechnology for the biologist. J. Leuk. Biol., 78(3):585-592.

[23]Meng, H., Xu, K., Xu, Y., et al., 2014. Nanocapsules based on mPEGylated artesunate prodrug and its cytotoxicity. Coll. Surf. B: Biointer., 115:164-169.

[24]Mesembe, O.E., Ivang, A.E., Udo-Attah, G., et al., 2004. A morphometric study of the teratogenic effect of artesunate on the central nervous system of the Wistar rats foetus. Nig. J. Physiol. Sci., 19(1):92-97.

[25]National Research Council, 2010. Guide for the Care and Use of Laboratory Animals. National Academies Press, Washington, DC.

[26]Nguyen, H.T., Tran, T.H., Kim, J.O., et al., 2015. Enhancing the in vitro anti-cancer efficacy of artesunate by loading into poly D,L-lactide-co-glycolide (PLGA) nanoparticles. Arch. Pharm. Res., 38(5):716-724.

[27]Nobbmann, U.L.F., 2014. Polydispersity—what does it mean for DLS and chromatography? http://www.materials-talks.com/blog/2014/10/23/polydispersity-what-does-it-mean-for-dls-and-chromatography [accessed on Oct. 24, 2016]

[28]Nordström, P., 2011. Formulation of Polymeric Nanoparticles Encapsulating and Releasing a New Hydrophobic Cancer Drug. MS Thesis, Chalmers University of Technology, Göteborg, Sweden.

[29]Panda, A., Meena, J., Katara, R., et al., 2016. Formulation and characterization of clozapine and risperidone co-entrapped spray-dried PLGA nanoparticles. Pharm. Dev. Technol., 21(1):43-53.

[30]Pradhan, R., Poudel, B.K., Ramasamy, T., et al., 2013. Docetaxel loaded polylactic acid-co-glycolic acid nanoparticles: formulation, physicochemical characterization and cytotoxicity studies. J. Nanosci. Nanotechnol., 13(8):5948-5956.

[31]Tona, L., Mesia, K., Ngimbi, N.P., et al., 2001. In vivo antimalarial activity of Cassia occindentalis, Morinda morindoides and Phyllanthus niruri. Ann. Trop. Med. Parasitol., 95(1):47-57.

[32]White, T.E., Bushdid, P.B., Ritter, S., et al., 2006. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Def. Res. Part B: Dev. Reprod. Toxicol., 77(5):413-429.

[33]Woerdenbag, H.J., Moskal, T.A., Pras, N., et al., 1993. Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J. Nat. Prod., 56(6):849-856.

[34]Wohlfart, S., Khalansky, A.S., Gelperina, S., et al., 2011. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers.

[35]PLoS ONE, 6:e19121.

[36]Zhang, Z.P., Feng, S.S., 2006. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials, 27(21):4025-4033.